Additionally, we have demonstrated in vivo using the PDX model that targeting GCH1 could potentiate the sensitivity of tumor cells to PARP inhibitors and markedly inhibit tumor growth without producing excessive toxic side effects. This evidence concerns the gene GCH1 and neoplasm.